Sickle Cell Disease Research: Current Studies, Clinical Trials, and What’s Coming Next
Published: 25 Apr 2026
The last decade has been the most productive period in the history of sickle cell disease research. After decades of relative neglect — a neglect that is inseparable from the racial demographics of the disease — scientific investment has accelerated, regulatory pathways have been fast-tracked, and two landmark gene therapies received FDA approval in December 2023.
That progress is real. But it is incomplete. Access to new treatments remains deeply inequitable. Many patients — particularly adults, patients in rural areas, and patients in low-income countries where sickle cell disease is most prevalent — will not benefit from the scientific advances of the last decade without significant changes in how treatments are priced, approved, and distributed.
Understanding the current state of sickle cell disease research — what has been approved, what is in clinical trials, and what the remaining challenges are — is essential knowledge for advocates, patients, clinicians, and anyone working to advance the field.
Recent Approvals: A Historic Moment for the Sickle Cell Community
In December 2023, the FDA approved two gene-based therapies for sickle cell disease in the same week — a milestone that would have seemed impossible a generation ago.
Casgevy (exagamglogene autotemcel), developed by Vertex Pharmaceuticals and CRISPR Therapeutics, uses CRISPR-Cas9 gene editing technology to modify a patient’s own stem cells — turning on a gene that produces fetal hemoglobin, which does not sickle. Casgevy was the first approved therapy using CRISPR gene editing for any disease.
Lyfgenia (lovotibeglogene autotemcel), developed by bluebird bio, uses a lentiviral vector to deliver a functional copy of the hemoglobin gene into a patient’s stem cells.
Both therapies require harvesting the patient’s stem cells, modifying them in a laboratory, administering chemotherapy to clear the patient’s existing bone marrow, and then infusing the modified cells. The process takes months, requires specialized treatment centers, and carries significant short-term risks — including from the chemotherapy conditioning regimen.
The price tags — $2.2 million for Casgevy and $3.1 million for Lyfgenia — have become central to the advocacy conversation about equitable access.Earlier approvals that remain important parts of the treatment landscape include voxelotor (Oxbryta), which reduces sickling by increasing hemoglobin’s affinity for oxygen, and crizanlizumab (Adakveo), which reduces pain crises by preventing sickle cells from adhering to blood vessel walls.
What Is Currently in Clinical Trials
The sickle cell disease research pipeline remains active beyond gene therapy. Several areas of investigation are particularly promising.
Next-generation gene therapies
Multiple programs are exploring approaches that may be less complex, less toxic, or more broadly accessible than current gene therapy options. These include in vivo gene editing approaches — where the gene editing happens inside the patient’s body rather than in a laboratory — which could potentially be administered as an infusion rather than requiring the intensive bone marrow transplant process.
Fetal hemoglobin induction
Beyond gene therapy, researchers are exploring small molecule approaches to increasing fetal hemoglobin production. If an oral medication could achieve the fetal hemoglobin induction that currently requires gene therapy, access could be dramatically broadened.
Anti-inflammatory and anti-sickling agents
Research continues on compounds that target the inflammatory and adhesive mechanisms that contribute to vaso-occlusive crises, building on the mechanism established by crizanlizumab.
Stem cell transplant improvements
Research into reduced-intensity conditioning regimens — making the bone marrow transplant process less toxic — could make curative stem cell transplant accessible to a broader population of patients.
Patient-reported outcomes research
An increasingly important area of sickle cell research focuses on understanding the patient experience — chronic pain, fatigue, mental health burden, quality of life — in ways that can inform clinical trial design and regulatory decision-making.
The Clinical Trial Enrollment Challenge in Sickle Cell
Clinical trials in sickle cell disease face several specific enrollment challenges that advocacy organizations can help address.
Small patient populations
Even within the rare disease category, sickle cell disease has a relatively small population of patients meeting eligibility criteria for any given trial. This makes enrollment slow and geographically challenging.
Medical mistrust
The history of unethical medical research targeting Black Americans — from Tuskegee to countless lesser-known examples — has created justified skepticism about clinical trial participation in the communities most affected by sickle cell disease. Addressing this requires more than education campaigns. It requires authentic relationships with community organizations, transparent communication about risks and benefits, and demonstrable commitment to patient interests over sponsor interests.
Trial burden
Many sickle cell trials require frequent clinic visits, extensive testing, and significant time commitments. For patients who are already managing a chronic illness, employment, family responsibilities, and limited access to transportation, trial participation can be prohibitively burdensome.
Inadequate representation of adults
Historically, much of the sickle cell research focus has been on children. Clinical trials often enroll pediatric patients first, with adult trials following years later. Adults with sickle cell disease — who represent the majority of the living sickle cell population — are underrepresented in research.
Patient advocacy organizations are the most effective mechanism for addressing these challenges — through trusted community relationships, education about specific trials, support for trial participation logistics, and advocacy for patient-centered trial design.
What the Advocacy Community Needs to Know
Several developments in sickle cell research have direct implications for advocacy organizations and the patients they serve.
Access advocacy is now the frontline
The science has advanced faster than the access infrastructure. The two approved gene therapies are transformative in their potential — and inaccessible to most patients at current prices. Advocacy for insurance coverage, Medicaid access, and pricing reform is one of the most urgent priorities in the field.
Informed consent and community trust must be central to trial design
Trials that engage advocacy organizations in their design — not just their execution — consistently perform better on enrollment and produce research that is more relevant to patients. Advocacy organizations should be at the table when trial protocols are being designed, not just when recruitment is underway.
International access is a growing issue
The burden of sickle cell disease is global — Nigeria alone has more people with sickle cell disease than the entire United States. Research that is conducted primarily in high-income countries and approved at prices accessible only in those countries is not solving the global problem. International advocacy coordination is becoming more important.
Patient-reported outcomes research needs support
Understanding the lived experience of sickle cell disease — chronic pain, fatigue, mental health, quality of life — requires data that comes from patients themselves. Advocacy organizations are well-positioned to support this research and to advocate for regulatory frameworks that take patient-reported outcomes seriously.
Frequently Asked Questions
Sickle cell disease research is advancing rapidly. Two gene therapies were approved by the FDA in December 2023. Multiple other treatments are approved or in clinical trials. The remaining challenges are primarily about access, equity, and ensuring that research progress translates into real improvements in patient outcomes.
Bone marrow and stem cell transplant has provided functional cures for some patients. The two FDA-approved gene therapies offer potential functional cures for a broader population, though access, cost, and treatment complexity remain significant barriers. Research into more accessible curative approaches is ongoing.
ClinicalTrials.gov maintains a searchable database of all registered clinical trials. The Sickle Cell Disease Association of America and disease-specific advocacy organizations also maintain resources for connecting patients with trial opportunities. Elevate Impact’s platform connects patients and advocates with researchers and institutions in the sickle cell community.
Factors include small and geographically dispersed patient populations, historical and ongoing medical mistrust in communities disproportionately affected by the disease, significant trial burden for patients already managing a chronic illness, and underrepresentation of adult patients in research.
By educating patients about specific trials, addressing concerns about participation, advocating for patient-centered trial design, supporting participation logistics, and maintaining community trust relationships with research institutions over time.
Elevate Impact is building the platform and community infrastructure that connects patient advocacy organizations with clinical researchers and industry partners in the sickle cell and rare disease space — supporting the kind of authentic, structured collaboration that produces better research and more equitable outcomes.
Sickle cell disease research is at a genuine inflection point. The science has never been more promising. The remaining work — making that science accessible, equitable, and grounded in authentic community partnership — requires advocates, clinicians, researchers, and industry to work together in ways they have not always managed.
Elevate Impact is here to support that work.
